Skip to main content

Sensei Biotherapeutics, Inc. (SNSE)

NASDAQ: SNSE · IEX Real-Time Price · USD
7.05 0.08 (1.15%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap215.65M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out30.59M
EPS (ttm)-2.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume78,224
Open6.95
Previous Close6.97
Day's Range6.71 - 7.10
52-Week Range6.68 - 26.50
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 3, 2021

About SNSE

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which furt...

IndustryBiotechnology
IPO DateFeb 4, 2021
Employees30
Stock ExchangeNASDAQ
Ticker SymbolSNSE
Full Company Profile

Financial Performance

Financial Statements

News

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th An...

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...

3 weeks ago - GlobeNewsWire

Sensei Biotherapeutics, Inc. (SNSE) Upgraded to Buy: Here's Why

Sensei Biotherapeutics, Inc. (SNSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program

- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model –

2 months ago - GlobeNewsWire

Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...

2 months ago - GlobeNewsWire

These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday

You might not have heard of them, but one went up big while the other served up a massive disappointment.

Other symbols:CERE
3 months ago - The Motley Fool

Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal A...

- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs -

3 months ago - GlobeNewsWire

5 Stocks With High Guru and Insider Buys in the Past 3 Months

According to the Double Buys page, a Premium feature of GuruFocus, five stocks that had multiple guru and insider buys during the second quarter are PennyMac Financial Services inc. ( PFSI , Financial),...

Other symbols:HAYWPFSIPTONVST
4 months ago - GuruFocus

Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patient...

– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated –

5 months ago - GlobeNewsWire

Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update

- ImmunoPhage™ platform programs and the VISTA program continue to advance -

5 months ago - GlobeNewsWire

Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D.

BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a  clinical-stage immunotherapy company focused on the discovery and development of next generati...

5 months ago - GlobeNewsWire

Sensei Biotherapeutics Appoints Jessie M. English, Ph.D.

Entrepreneurial leader brings expertise growing biotech platform companies Entrepreneurial leader brings expertise growing biotech platform companies

6 months ago - GlobeNewsWire

Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update

-Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds –

6 months ago - GlobeNewsWire

7 Stocks With Significant Insider Buying

There are many reasons an insider might sell. But there is only one reason for insider buying; insiders think the stock will trade higher.

Other symbols:DHRDTEIRWDNLSPRMWTREE
7 months ago - InvestorPlace

Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference

BOSTON and ROCKVILLE, Md., March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutic...

7 months ago - GlobeNewsWire

7 Beaten Down Stocks With Significant Insider Buying

If the insiders are buying, other investors should at least pay attention. These seven stocks are ones to keep an eye on here.

Other symbols:CERNDDHSICINCYMTDNUS
7 months ago - InvestorPlace

Sensei Biotherapeutics Announces Closing of Initial Public Offering

BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics...

8 months ago - GlobeNewsWire

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics...

8 months ago - GlobeNewsWire

Sensei Biotherapeutics Announces Launch of Initial Public Offering

BOSTON & ROCKVILLE, Md.--Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced...

8 months ago - Business Wire

Sensei Biotherapeutics IPO Registration Document (S-1)

Sensei Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC

Cancer biotech Sensei Biotherapeutics files for a $100 million IPO

Sensei Biotherapeutics, a Phase 2 biotech developing bacteriophage-based therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

9 months ago - NASDAQ

Uma Thurman invests in cancer immunotherapy company

Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston research and development hub last year, has attracted high-profile investors for its $30 million Series B round.

9 months ago - BostInno